Literature DB >> 2428616

Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

L Banks, G Matlashewski, L Crawford.   

Abstract

The isolation and construction of a complete human p53 cDNA and subsequent expression in monkey cells is described. A set of new anti-(human p53) monoclonal antibodies has also been obtained and used to show the expression of the human p53 cDNA in cos-l cells. These antibodies enable the specific detection of human p53, which is synthesised in the presence of p53 from other species. Fusion proteins of p53 with beta-galactosidase were used firstly as antigen and secondly, in conjunction with competition assays, to localise the determinants recognized by the antibodies. At least two previously unrecognized epitopes are involved and two of the antibodies are human-p53-specific. The epitopes are denaturation-resistant and the antibodies are, therefore, valuable for immunoblotting as well as immunoprecipitation and enzyme-linked immunoassay. Transfection of plasmids containing complete human p53 cDNA into monkey (cos-l) cells cause expression of human p53 recognized by the monoclonal antibodies. Control plasmids did not induce immunoreactive protein.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428616     DOI: 10.1111/j.1432-1033.1986.tb09919.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  157 in total

1.  Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins.

Authors:  S S Lee; B Glaunsinger; F Mantovani; L Banks; R T Javier
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Clinical and Histological Prognostic Factors in Axillary Node-Negative BreastCancer: Univariate and Multivariate Analysis with Relation to 5-Year Recurrence.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

3.  p53 shares an antigenic determinant with proteins of 92 and 150 kilodaltons that may be involved in senescence of human cells.

Authors:  S J van den Heuvel; S I The; B Klein; A G Jochemsen; A Zantema; A J van der Eb
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

5.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.

Authors:  B S Chozick; D L Benzil; E G Stopa; J C Pezzullo; N W Knuckey; M H Epstein; S D Finkelstein; P W Finch
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

7.  The expression of biologically active human p53 in Leishmania cells: a novel eukaryotic system to produce recombinant proteins.

Authors:  W W Zhang; H Charest; G Matlashewski
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

8.  Ultraviolet-induced p53 mutations in atypical fibroxanthoma.

Authors:  A P Dei Tos; R Maestro; C Doglioni; D Gasparotto; M Boiocchi; L Laurino; C D Fletcher
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

10.  Overexpression of p53 protein in Barrett's syndrome with malignant transformation.

Authors:  J F Fléjou; F Potet; F Muzeau; F Le Pelletier; F Fékété; D Hénin
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.